Skip to main content
Premium Trial:

Request an Annual Quote

Altana Opens Research Institute near Boston with Focus on Genomics, Proteomics

NEW YORK, June 13 - Altana Pharma, the pharmaceutical division of Altana, opened a research center in Waltham, Mass., today  that will focus on genomics and proteomics as well as bioinformatics.

 

The center, called Altana Research Institute, is part of a five-and-a-half-year collaboration between Constance, Germany-based Altana Pharma and Munich-based GPC Biotech. Work on the center, which houses about 50 scientists, began in November 2001. Altana, of Bad Homburg, Germany, will invest a total of about $120 million in the institute.

 

Research at the ARI will focus on gastroenterology, respiratory diseases, and oncology, core areas of Altana Pharma.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.